In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice.
Marina Kremyanskaya, MD
Advertisement
Articles by Marina Kremyanskaya, MD
Advertisement
Latest Updated Articles
Clarifying the Use of Ruxolitinib in Patients With MyelofibrosisPublished: July 15th 2013 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
How Can Lower-Income Countries Maintain Representation in Clinical Trials?
5
